Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$1.74
0.01140.66%
Last update: Jun 10, 1:32 PM
Chemomab Therapeutics Ltd Analyst Ratings
CMMBNASDAQ
Chemomab Therapeutics Analyst Ratings and Price Targets | NASDAQ:CMMB | Benzinga
Chemomab Therapeutics Ltd has a consensus price target of $13 based on the ratings of 3 analysts. The high is $25 issued by Oppenheimer on August 27, 2025. The low is $7 issued by Maxim Group on February 20, 2025. The 3 most-recent analyst ratings were released by Oppenheimer, Oppenheimer, and Maxim Group on August 27, 2025, May 16, 2025, and February 20, 2025, respectively. With an average price target of $14 between Oppenheimer, Oppenheimer, and Maxim Group, there's an implied 703.95% upside for Chemomab Therapeutics Ltd from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Oppenheimer
Maxim Group
Roth MKM
1calculated from analyst ratings
Analyst Ratings for Chemomab Therapeutics
Loading calendar...
FAQ
What is the target price for Chemomab Therapeutics (CMMB) stock?
The latest price target for Chemomab Therapeutics (NASDAQ:CMMB) was reported by Oppenheimer on August 27, 2025. The analyst firm set a price target for $25.00 expecting CMMB to rise to within 12 months (a possible 1335.63% upside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Chemomab Therapeutics (CMMB)?
The latest analyst rating for Chemomab Therapeutics (NASDAQ:CMMB) was provided by Oppenheimer, and Chemomab Therapeutics maintained their outperform rating.
When was the last upgrade for Chemomab Therapeutics (CMMB)?
The last upgrade for Chemomab Therapeutics Ltd happened on May 6, 2024 when Oppenheimer raised their price target to $6. Oppenheimer previously had a perform for Chemomab Therapeutics Ltd.
When was the last downgrade for Chemomab Therapeutics (CMMB)?
There is no last downgrade for Chemomab Therapeutics.
When is the next analyst rating going to be posted or updated for Chemomab Therapeutics (CMMB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Chemomab Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Chemomab Therapeutics was filed on August 27, 2025 so you should expect the next rating to be made available sometime around August 27, 2026.
Is the Analyst Rating Chemomab Therapeutics (CMMB) correct?
While ratings are subjective and will change, the latest Chemomab Therapeutics (CMMB) rating was a maintained with a price target of $10.00 to $25.00. The current price Chemomab Therapeutics (CMMB) is trading at is $1.74, which is out of the analyst’s predicted range.
